Voruciclib, a CDK9 inhibitor, Downregulates MYC and MCL1 and Inhibits Proliferation in Heme and Solid Tumor Models
Time: 8:30 am
day: Day One
Details:
- Targeting transcription and phosphorylation-mediated protein degradation as an indirect mechanism to downregulate MYC and MCL1
- Voruciclib synergizes with KRAS G12C and BCL2 inhibitors in preclinical solid tumor and heme malignancy models
- Voruciclib, in combination with venetoclax, is under clinical investigation in AML
